Purple Biotech (PPBT) Common Equity (2014 - 2026)

Purple Biotech (PPBT) has reported Common Equity for 13 consecutive years, with $12.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity fell 61.89% year-over-year to $12.2 million in Q2 2026; TTM through Jun 2026 was $12.2 million, a 61.89% decrease from a year earlier, with the FY2025 full-year figure at $9.7 million, down 70.65% from the prior year.
• Common Equity was $12.2 million for Q2 2026 at Purple Biotech, up from $9.7 million in the prior quarter.
• Over five years, Common Equity peaked at $58.3 million in Q1 2022 and troughed at $9.7 million in Q4 2025.
• A 5-year average of $34.9 million and a median of $32.9 million in 2024 frame the typical range for Common Equity.
• The widest YoY moves for Common Equity: up 11.36% in 2025, down 70.65% in 2025.
• Over 5 years, Common Equity stood at $47.1 million in 2022, then fell by 27.18% to $34.3 million in 2023, then dropped by 4.04% to $32.9 million in 2024, then slumped by 70.65% to $9.7 million in 2025, then gained by 26.44% to $12.2 million in 2026.
• The last three Common Equity figures came in at $12.2 million (Q2 2026), $9.7 million (Q1 2026), and $9.7 million (Q4 2025), per Business Quant data.